| Immune evasion in cancer: Mechanistic basis and therapeutic strategies DS Vinay, EP Ryan, G Pawelec, WH Talib, J Stagg, E Elkord, T Lichtor, ... Seminars in cancer biology 35, S185-S198, 2015 | 1642 | 2015 |
| Broad targeting of resistance to apoptosis in cancer RM Mohammad, I Muqbil, L Lowe, C Yedjou, HY Hsu, LT Lin, MD Siegelin, ... Seminars in cancer biology 35, S78-S103, 2015 | 743 | 2015 |
| Sustained proliferation in cancer: Mechanisms and novel therapeutic targets MA Feitelson, A Arzumanyan, RJ Kulathinal, SW Blain, RF Holcombe, ... Seminars in cancer biology 35, S25-S54, 2015 | 727 | 2015 |
| Tissue invasion and metastasis: Molecular, biological and clinical perspectives WG Jiang, AJ Sanders, M Katoh, H Ungefroren, F Gieseler, M Prince, ... Seminars in cancer biology 35, S244-S275, 2015 | 567 | 2015 |
| Broad targeting of angiogenesis for cancer prevention and therapy Z Wang, C Dabrosin, X Yin, MM Fuster, A Arreola, WK Rathmell, ... Seminars in cancer biology 35, S224-S243, 2015 | 514 | 2015 |
| Cancer prevention and therapy through the modulation of the tumor microenvironment SC Casey, A Amedei, K Aquilano, AS Azmi, F Benencia, D Bhakta, ... Seminars in cancer biology 35, S199-S223, 2015 | 364 | 2015 |
| Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition LR Ferguson, H Chen, AR Collins, M Connell, G Damia, S Dasgupta, ... Seminars in cancer biology 35, S5-S24, 2015 | 358 | 2015 |
| Designing a broad-spectrum integrative approach for cancer prevention and treatment KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ... Seminars in cancer biology 35, S276-S304, 2015 | 304 | 2015 |
| Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors C Dufes, WN Keith, A Bilsland, I Proutski, IF Uchegbu, AG Schätzlein Cancer research 65 (18), 8079-8084, 2005 | 172 | 2005 |
| Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds ARMR Amin, PA Karpowicz, TE Carey, J Arbiser, R Nahta, ZG Chen, ... Seminars in cancer biology 35, S55-S77, 2015 | 142 | 2015 |
| Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954 JA Plumb, A Bilsland, R Kakani, J Zhao, RM Glasspool, RJ Knox, ... Oncogene 20 (53), 7797-7803, 2001 | 137 | 2001 |
| A multi-targeted approach to suppress tumor-promoting inflammation AK Samadi, A Bilsland, AG Georgakilas, A Amedei, A Amin, A Bishayee, ... Seminars in cancer biology 35, S151-S184, 2015 | 132 | 2015 |
| Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms CJ Anderson, SF Hoare, M Ashcroft, AE Bilsland, WN Keith Oncogene 25 (1), 61-69, 2006 | 131 | 2006 |
| Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase AE Bilsland, CJ Anderson, AJ Fletcher-Monaghan, F McGregor, ... Oncogene 22 (3), 370-380, 2003 | 124 | 2003 |
| A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT K Lafferty-Whyte, CJ Cairney, MB Will, N Serakinci, MG Daidone, ... Oncogene 28 (43), 3765-3774, 2009 | 98 | 2009 |
| Therapeutic targeting of replicative immortality P Yaswen, KL MacKenzie, WN Keith, P Hentosh, F Rodier, J Zhu, ... Seminars in cancer biology 35, S104-S128, 2015 | 85 | 2015 |
| Activation of telomerase rna gene promoter activity by NF-Y, Sp1, and the retinoblastoma protein and repression by Sp3 JQ Zhao, RM Glasspool, SF Hoare, A Bilsland, I Szatmari, WN Keith Neoplasia 2 (6), 531-539, 2000 | 66 | 2000 |
| Telomerase-directed molecular therapeutics WN Keith, A Bilsland, TRJ Evans, RM Glasspool Expert reviews in molecular medicine 4 (10), 1-25, 2002 | 60 | 2002 |
| Drug Insight: cancer cell immortality—telomerase as a target for novel cancer gene therapies WN Keith, A Bilsland, M Hardie, TRJ Evans Nature Clinical Practice Oncology 1 (2), 88-96, 2004 | 58 | 2004 |
| Cancer cell senescence: a new frontier in drug development CJ Cairney, AE Bilsland, TRJ Evans, J Roffey, DC Bennett, M Narita, ... Drug discovery today 17 (5-6), 269-276, 2012 | 57 | 2012 |
